Dallah Healthcare Company SJSC
SAU:4004
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dallah Healthcare Company SJSC
SAU:4004
|
SA |
|
S4 Capital PLC
LSE:SFOR
|
UK |
|
P
|
Pavilion Real Estate Investment Trust
KLSE:PAVREIT
|
MY |
|
Tejon Ranch Co
NYSE:TRC
|
US |
|
Vetanova Inc
OTC:VTNA
|
US |
|
Tritax Big Box Reit PLC
LSE:BBOX
|
UK |
|
C
|
Centuria Industrial Reit
ASX:CIP
|
AU |
|
Cake Box Holdings PLC
LSE:CBOX
|
UK |
Wall Street
Price Targets
Price Targets Summary
Dallah Healthcare Company SJSC
According to Wall Street analysts, the average 1-year price target for
Dallah Healthcare Company SJSC
is 139.43 SAR
with a low forecast of 109.59 SAR and a high forecast of 183.75 SAR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Dallah Healthcare Company SJSC's stock price target?
Price Target
139.43
SAR
According to Wall Street analysts, the average 1-year price target for
Dallah Healthcare Company SJSC
is 139.43 SAR
with a low forecast of 109.59 SAR and a high forecast of 183.75 SAR.
What is Dallah Healthcare Company SJSC's Revenue forecast?
Projected CAGR
9%
For the last 14 years the
compound annual growth rate for
Dallah Healthcare Company SJSC's revenue is
16%.
The projected
CAGR
for the next 2 years is
9%.
What is Dallah Healthcare Company SJSC's Operating Income forecast?
Projected CAGR
16%
For the last 14 years the
compound annual growth rate for
Dallah Healthcare Company SJSC's operating income is
14%.
The projected
CAGR
for the next 3 years is
16%.
What is Dallah Healthcare Company SJSC's Net Income forecast?
Projected CAGR
10%
For the last 14 years the
compound annual growth rate for
Dallah Healthcare Company SJSC's net income is
12%.
The projected
CAGR
for the next 2 years is
10%.
